Times Opinion: An erratic FDA is a threat to innovation - Chattanooga Times Free Press

Times Opinion: An erratic FDA is a threat to innovation  Chattanooga Times Free Press

Moderna (MRNA) Valuation Check As Multi Pathogen mRNA Study Completion And FDA Shifts Draw Fresh ...

Moderna (MRNA) Valuation Check As Multi Pathogen mRNA Study Completion And FDA Shifts Draw Fresh Focus  Yahoo Finance

The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery - FinancialContent

The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery  FinancialContent

Moderna Settles Patent Litigation with Arbutus et al. - JD Supra

Moderna Settles Patent Litigation with Arbutus et al.  JD Supra

GSK catches up to Pfizer, Moderna with FDA expansion for Arexvy - Fierce Pharma

GSK catches up to Pfizer, Moderna with FDA expansion for Arexvy  Fierce Pharma

Moderna says CEO Stéphane Bancel's 2025 total compensation was $19.9 million - SEC filing - marke...

Moderna says CEO Stéphane Bancel's 2025 total compensation was $19.9 million - SEC filing  marketscreener.com

Moderna | History, Innovation, Challenges, & Facts | Britannica Money - Britannica

Moderna | History, Innovation, Challenges, & Facts | Britannica Money  Britannica

Moderna to pay Roivant up to $2.25 billion to settle patent lawsuit behind mRNA vaccines - statne...

Moderna to pay Roivant up to $2.25 billion to settle patent lawsuit behind mRNA vaccines  statnews.com

Moderna to pay up to $2.25B to end mRNA vaccine patent fight - BioPharma Dive

Moderna to pay up to $2.25B to end mRNA vaccine patent fight  BioPharma Dive

Moderna’s 2-in-1 flu and COVID vaccine shows encouraging results in small trial - CIDRAP

Moderna’s 2-in-1 flu and COVID vaccine shows encouraging results in small trial  CIDRAP

Form DEFA14A Moderna, Inc. - StreetInsider

Form DEFA14A Moderna, Inc.  StreetInsider

FDA agrees to review Moderna’s mRNA flu vaccine application in a reversal - CNBC

FDA agrees to review Moderna’s mRNA flu vaccine application in a reversal  CNBC

FDA reverses course on Moderna flu shot - NPR

FDA reverses course on Moderna flu shot  NPR

Moderna settles patent lawsuits over COVID vaccine for $950 million - WBUR

Moderna settles patent lawsuits over COVID vaccine for $950 million  WBUR

F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine - The New York Times - The Ne...

F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine - The New York Times  The New York Times

March 10 Business Watch: Syngenta ends paraquat production; Moderna settles lipid patent case - C...

March 10 Business Watch: Syngenta ends paraquat production; Moderna settles lipid patent case  Chemical & Engineering News

CEPI to Fund Pivotal Phase 3 Trial for Moderna’s mRNA Pandemic Influenza Candidate - CEPI

CEPI to Fund Pivotal Phase 3 Trial for Moderna’s mRNA Pandemic Influenza Candidate  CEPI

Moderna (MRNA) Declines More Than Market: Some Information for Investors - Yahoo Finance

Moderna (MRNA) Declines More Than Market: Some Information for Investors  Yahoo Finance

Moderna’s reset hinges on oncology - statnews.com

Moderna’s reset hinges on oncology  statnews.com

FDA reverses course, agrees to review Moderna’s flu vaccine - statnews.com

FDA reverses course, agrees to review Moderna’s flu vaccine  statnews.com

Moderna Pops As Vinay Prasad, The FDA's Controversial Vaccine Head, Will Depart In April - Invest...

Moderna Pops As Vinay Prasad, The FDA's Controversial Vaccine Head, Will Depart In April  Investor's Business Daily

Quo Vadis mRNA Vaccine Technology? The State of the IP Lawsuits - JD Supra

Quo Vadis mRNA Vaccine Technology? The State of the IP Lawsuits  JD Supra

FDA agrees to review Moderna mRNA flu vaccine in dramatic reversal - Scientific American

FDA agrees to review Moderna mRNA flu vaccine in dramatic reversal  Scientific American

Moderna says FDA will now consider its new mRNA flu shot after initial refusal - PBS

Moderna says FDA will now consider its new mRNA flu shot after initial refusal  PBS

FDA's reversal on Moderna flu shot bid followed White House pressure - Politico

FDA's reversal on Moderna flu shot bid followed White House pressure  Politico

FDA accepts filing for Moderna flu vaccine after swift rethink - fiercebiotech.com

FDA accepts filing for Moderna flu vaccine after swift rethink  fiercebiotech.com

FDA reverses course and will review Moderna’s mRNA-based flu vaccine - The Guardian

FDA reverses course and will review Moderna’s mRNA-based flu vaccine  The Guardian

Double-reverse: FDA now says it will review Moderna’s mRNA flu vaccine - CIDRAP

Double-reverse: FDA now says it will review Moderna’s mRNA flu vaccine  CIDRAP

Is Moderna (MRNA) Pricing Too High After Its Recent 70% Year To Date Rally - Yahoo Finance

Is Moderna (MRNA) Pricing Too High After Its Recent 70% Year To Date Rally  Yahoo Finance

Moderna chief: Company won’t invest in new late-stage vaccine trials - CIDRAP

Moderna chief: Company won’t invest in new late-stage vaccine trials  CIDRAP

FDA Reverses Course, Will Review Moderna’s mRNA Flu Vaccine - The American Journal of Managed Car...

FDA Reverses Course, Will Review Moderna’s mRNA Flu Vaccine  The American Journal of Managed Care® (AJMC®)

Moderna’s combination flu, COVID shot wins over European drug regulators - BioPharma Dive

Moderna’s combination flu, COVID shot wins over European drug regulators  BioPharma Dive

FDA reverses course on Moderna’s flu vaccine - BioPharma Dive

FDA reverses course on Moderna’s flu vaccine  BioPharma Dive

FDA reverses course, will review Moderna’s mRNA flu vaccine candidate - The Hill

FDA reverses course, will review Moderna’s mRNA flu vaccine candidate  The Hill

F.D.A. Refuses to Review Moderna Flu Vaccine - The New York Times - The New York Times

F.D.A. Refuses to Review Moderna Flu Vaccine - The New York Times  The New York Times

FDA Refuses to Review Moderna's Influenza Vaccine for Potential Approval - Contagion Live

FDA Refuses to Review Moderna's Influenza Vaccine for Potential Approval  Contagion Live

State's top health official: FDA's reversal on Moderna's flu vaccine could ‘chill the market’ - WGBH

State's top health official: FDA's reversal on Moderna's flu vaccine could ‘chill the market’  WGBH

Moderna: Pipeline Hope Won't Pay The Bills (NASDAQ:MRNA) - Seeking Alpha

Moderna: Pipeline Hope Won't Pay The Bills (NASDAQ:MRNA)  Seeking Alpha

FDA Reverses Course on Moderna’s mRNA Flu Shot Application, Promising August Decision - BioSpace

FDA Reverses Course on Moderna’s mRNA Flu Shot Application, Promising August Decision  BioSpace

Key Factors Contributing to Uncertainty in Moderna's mRNA Vaccine Review - Pharmaceutical Executive

Key Factors Contributing to Uncertainty in Moderna's mRNA Vaccine Review  Pharmaceutical Executive

FDA’s rejection of Moderna threatens to stifle broader vaccine industry - statnews.com

FDA’s rejection of Moderna threatens to stifle broader vaccine industry  statnews.com

Prasad overruled FDA staff to reject Moderna’s flu vaccine application - statnews.com

Prasad overruled FDA staff to reject Moderna’s flu vaccine application  statnews.com

‘Regulatory whiplash’ as FDA decides to review Moderna flu shot - Chemical & Engineering News

‘Regulatory whiplash’ as FDA decides to review Moderna flu shot  Chemical & Engineering News

Moderna says FDA will now review its new flu vaccine, reversing earlier decision - CBS News

Moderna says FDA will now review its new flu vaccine, reversing earlier decision  CBS News

FDA reverses course and will review Moderna’s mRNA-based flu shot - The Washington Post

FDA reverses course and will review Moderna’s mRNA-based flu shot  The Washington Post

Court Rejects Two Moderna Defenses in mRNA Vaccine Patent Row With Arbutus - BioSpace

Court Rejects Two Moderna Defenses in mRNA Vaccine Patent Row With Arbutus  BioSpace

Mixed options sentiment in Moderna with shares down 1.9% - TipRanks

Mixed options sentiment in Moderna with shares down 1.9%  TipRanks

Moderna (MRNA) Climbs 16% as Arbutus-Genevant Legal Battle Clears - Yahoo Finance

Moderna (MRNA) Climbs 16% as Arbutus-Genevant Legal Battle Clears  Yahoo Finance

Moderna CEO addresses company future in 2025 shareholder letter - BioProcess International

Moderna CEO addresses company future in 2025 shareholder letter  BioProcess International

FDA reverses course, refuses to review Moderna’s application for new mRNA flu vaccine - CIDRAP

FDA reverses course, refuses to review Moderna’s application for new mRNA flu vaccine  CIDRAP

European health agency recommends approving Moderna’s combined flu, COVID vaccine - The Hill

European health agency recommends approving Moderna’s combined flu, COVID vaccine  The Hill

Scientists identify new spinosaurid, Moderna flu shot back on track, universal inhaled vaccine sh...

Scientists identify new spinosaurid, Moderna flu shot back on track, universal inhaled vaccine shows promise  Scientific American

Moderna will pay up to $2.25B to end COVID vaccine patent fight - The News Journal

Moderna will pay up to $2.25B to end COVID vaccine patent fight  The News Journal

Moderna, Inc. (MRNA): A Bull Case Theory - Yahoo Finance

Moderna, Inc. (MRNA): A Bull Case Theory  Yahoo Finance

Moderna Vaccine Patent Deal Sets Up High-Stakes Immunity Appeal - Bloomberg Law News

Moderna Vaccine Patent Deal Sets Up High-Stakes Immunity Appeal  Bloomberg Law News

How Moderna, the company that helped save the world, unraveled - statnews.com

How Moderna, the company that helped save the world, unraveled  statnews.com

Moderna says FDA refuses to review its application for experimental flu shot - CNBC

Moderna says FDA refuses to review its application for experimental flu shot  CNBC

White House frustration fueled FDA’s Moderna walkback: reports - fiercebiotech.com

White House frustration fueled FDA’s Moderna walkback: reports  fiercebiotech.com

A Fresh Look At Moderna (MRNA) Valuation After A Sharp Share Price Rebound - Yahoo Finance

A Fresh Look At Moderna (MRNA) Valuation After A Sharp Share Price Rebound  Yahoo Finance

Moderna hit with FDA refusal-to-file letter for mRNA flu shot, issues sharp rebuke of agency's ra...

Moderna hit with FDA refusal-to-file letter for mRNA flu shot, issues sharp rebuke of agency's rationale  fiercebiotech.com

FDA defends its decision to refuse review of Moderna's flu vaccine - Reuters

FDA defends its decision to refuse review of Moderna's flu vaccine  Reuters

FDA refuses to review Moderna’s influenza vaccine - statnews.com

FDA refuses to review Moderna’s influenza vaccine  statnews.com

Jefferies Financial Group Inc. Sells 32,310 Shares of Moderna, Inc. $MRNA - MarketBeat

Jefferies Financial Group Inc. Sells 32,310 Shares of Moderna, Inc. $MRNA  MarketBeat

Moderna investors prepare for a phase 3 reveal | ApexOnco - Clinical Trials news and analysis - O...

Moderna investors prepare for a phase 3 reveal | ApexOnco - Clinical Trials news and analysis  Oncology Pipeline

Delaware Court Narrows Moderna’s Invalidity Defenses Ahead of Arbutus LNP Patent Trial - IPWatchd...

Delaware Court Narrows Moderna’s Invalidity Defenses Ahead of Arbutus LNP Patent Trial  IPWatchdog.com

Moderna’s EU Backing For Combo Vaccine Shifts Respiratory Growth Focus - Yahoo Finance

Moderna’s EU Backing For Combo Vaccine Shifts Respiratory Growth Focus  Yahoo Finance

Moderna COVID vaccine 53% effective against adult hospitalization in 2024-25 season, data suggest...

Moderna COVID vaccine 53% effective against adult hospitalization in 2024-25 season, data suggest  CIDRAP

FDA reverses decision, will review Moderna’s mRNA flu vaccine - Healio

FDA reverses decision, will review Moderna’s mRNA flu vaccine  Healio

FDA Refuses to Review Moderna’s New Flu Shot - Time Magazine

FDA Refuses to Review Moderna’s New Flu Shot  Time Magazine

Moderna CMO Jacqueline Miller to step down - Reuters

Moderna CMO Jacqueline Miller to step down  Reuters

U.S. Health Officials Defend Rejection of Moderna’s Flu Vaccine - The New York Times - The New Yo...

U.S. Health Officials Defend Rejection of Moderna’s Flu Vaccine - The New York Times  The New York Times

IDWeek 2025: No signal for myocarditis in updated Moderna mRNA COVID vaccine - European AIDS Trea...

IDWeek 2025: No signal for myocarditis in updated Moderna mRNA COVID vaccine  European AIDS Treatment Group

An Erratic FDA Is a Threat to Innovation - Bloomberg.com

An Erratic FDA Is a Threat to Innovation  Bloomberg.com

FDA rejects Moderna’s mRNA flu vaccine application - for reasons with no basis in the law - The C...

FDA rejects Moderna’s mRNA flu vaccine application - for reasons with no basis in the law  The Conversation

IR Insights: Recapping Our Third Quarter 2025 Earnings Report - Moderna

IR Insights: Recapping Our Third Quarter 2025 Earnings Report  Moderna

Moderna Scores $54 Million From CEPI To Fund Bird Flu Vaccine - BioSpace

Moderna Scores $54 Million From CEPI To Fund Bird Flu Vaccine  BioSpace

Moderna takes on IO Biotech | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Moderna takes on IO Biotech | ApexOnco - Clinical Trials news and analysis  Oncology Pipeline

FDA Refuses To Review Moderna’s mRNA Flu Vaccine, Claims Trial Inadequacies - BioSpace

FDA Refuses To Review Moderna’s mRNA Flu Vaccine, Claims Trial Inadequacies  BioSpace

Moderna’s Multi-Pathogen mRNA Study Reaches Completion, Supporting a Broader Vaccine Platform - T...

Moderna’s Multi-Pathogen mRNA Study Reaches Completion, Supporting a Broader Vaccine Platform  TipRanks

Moderna to slash 10% of workforce as biotech cuts costs, Covid shot sales slow - CNBC

Moderna to slash 10% of workforce as biotech cuts costs, Covid shot sales slow  CNBC

Moderna to complete US mRNA manufacturing network with $140 million investment - Reuters

Moderna to complete US mRNA manufacturing network with $140 million investment  Reuters

Moderna halts development of birth defect vaccine after trial setback - Reuters

Moderna halts development of birth defect vaccine after trial setback  Reuters

Moderna secures $1.5B lifeline as it looks to break even in 2028 - BioPharma Dive

Moderna secures $1.5B lifeline as it looks to break even in 2028  BioPharma Dive

Moderna offloads late-stage rare disease drug to Recordati for $50M upfront - fiercebiotech.com

Moderna offloads late-stage rare disease drug to Recordati for $50M upfront  fiercebiotech.com

Moderna expands mRNA manufacturing in US at site in Norwood, MA - BioProcess International

Moderna expands mRNA manufacturing in US at site in Norwood, MA  BioProcess International

FDA to review Moderna’s mRNA-based flu vaccine - MS NOW

FDA to review Moderna’s mRNA-based flu vaccine  MS NOW

FDA refuses to review Moderna's influenza vaccine application - Reuters

FDA refuses to review Moderna's influenza vaccine application  Reuters

FDA’s abrupt flip-flop on Moderna’s mRNA flu shot highlights growing risks to drug-makers of inve...

FDA’s abrupt flip-flop on Moderna’s mRNA flu shot highlights growing risks to drug-makers of investing in vaccines  The Conversation

Moderna Teams With Recordati on Rare Disease mRNA Therapy for up to $160M - BioSpace

Moderna Teams With Recordati on Rare Disease mRNA Therapy for up to $160M  BioSpace

Moderna secures up to $54.3 million funding for bird flu vaccine from global coalition - Reuters

Moderna secures up to $54.3 million funding for bird flu vaccine from global coalition  Reuters

FDA declines to review Moderna application for new flu vaccine - The Guardian

FDA declines to review Moderna application for new flu vaccine  The Guardian

Moderna expects $1.9 billion in sales, trims costs forecast for 2025 - Reuters

Moderna expects $1.9 billion in sales, trims costs forecast for 2025  Reuters

Moderna’s mRNA Vaccine Refusal Comes Amid Global Advanced Therapies Push - BioSpace

Moderna’s mRNA Vaccine Refusal Comes Amid Global Advanced Therapies Push  BioSpace

Inside Moderna’s rapid rise — and precarious future - statnews.com

Inside Moderna’s rapid rise — and precarious future  statnews.com

Moderna - IBM

Moderna  IBM

Moderna R&D spend shrunk 31% in 2025 amid major pipeline reorg - fiercebiotech.com

Moderna R&D spend shrunk 31% in 2025 amid major pipeline reorg  fiercebiotech.com

Local health experts question FDA's refusal to review Moderna's application for a new mRNA flu va...

Local health experts question FDA's refusal to review Moderna's application for a new mRNA flu vaccine  WGBH

FDA refuses to review Moderna's mRNA flu shot - NBC News

FDA refuses to review Moderna's mRNA flu shot  NBC News

Moderna (MRNA) Chief Legal Officer logs RSU conversion and tax share disposition - Stock Titan

Moderna (MRNA) Chief Legal Officer logs RSU conversion and tax share disposition  Stock Titan

Moderna Is Curbing Investment in Vaccine Trials Due to US Backlash - Bloomberg.com

Moderna Is Curbing Investment in Vaccine Trials Due to US Backlash  Bloomberg.com